[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100490135":3},{"organization":4,"armGroups":7,"interventions":32,"overallOfficials":43,"centralContacts":48,"locations":53,"responsibleParty":77,"collaborators":80,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":38,"eligibilityCriteria":89,"healthyVolunteers":85,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":38,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":105,"overallStatus":56,"whyStopped":38,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Azienda Ospedaliero-Universitaria di Parma","OTHER",[8,14,17,20,23,26,29],{"label":9,"type":6,"description":10,"interventionNames":11},"long standing type 1 diabetes (> 20 yrs)","68Ga-exendin4 PET-CT scan +mixed meal test",[12,13],"Drug: 68Ga-exendin-4","Other: mixed meal test",{"label":15,"type":6,"description":10,"interventionNames":16},"newly diagnosed type 1 diabetes (\u003C 5yrs)",[12,13],{"label":18,"type":6,"description":10,"interventionNames":19},"long standing type 2 diabetes (> 20 yrs)",[12,13],{"label":21,"type":6,"description":10,"interventionNames":22},"newly diagnosed type 2 diabetes (\u003C6 months)",[12,13],{"label":24,"type":6,"description":10,"interventionNames":25},"pre-diabetes",[12,13],{"label":27,"type":6,"description":10,"interventionNames":28},"hyperinsulinemic",[12,13],{"label":30,"type":6,"description":10,"interventionNames":31},"control",[12,13],[33,39],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"DRUG","68Ga-exendin-4","68Ga-exendin4 PET-CT scan",[30,27,9,18,15,21,24],null,{"type":6,"name":40,"description":41,"armGroupLabels":42,"otherNames":38},"mixed meal test","before and after a standardized mixed meal venous blood samples will be collected at time intervals to measure plasma glucose, C-peptide,insulin, glucagon, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) curves",[30,27,9,18,15,21,24],[44],{"name":45,"affiliation":46,"role":47},"Riccardo Bonadonna, MD","Azienda Ospedaliero Universitaria di Parma, University of Parma","PRINCIPAL_INVESTIGATOR",[49],{"name":45,"role":50,"phone":51,"phoneExt":38,"email":52},"CONTACT","+390521033307","riccardo.bonadonna@unipr.it",[54],{"facility":55,"status":56,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"Azienda Ospedaliero Universitaria di Parma","RECRUITING","Parma","Pr","43126","Italy","IT",{"type":63,"coordinates":64},"Point",[65,66],10.32618,44.79935,{"lat":66,"lon":65},[69,73,75],{"name":70,"role":50,"phone":71,"phoneExt":38,"email":72},"Raffaella Aldigeri, MSc","+390521033306","raffaella.aldigeri@unipr.it",{"name":74,"role":50,"phone":38,"phoneExt":38,"email":38},"Alessandra Dei Cas, PhD",{"name":76,"role":50,"phone":38,"phoneExt":38,"email":38},"Livia Ruffini, MD",{"type":47,"investigatorFullName":78,"investigatorTitle":79,"investigatorAffiliation":5,"oldNameTitle":38,"oldOrganization":38},"Riccardo Bonadonna","Prof",[81],{"name":82,"class":6},"University of Parma","100490135","assessment-of-pancreatic-beta-cell-mass-and-function-by-positron-emission-tomography-imaging-in-human-diabetes-mellitus-100490135",false,"NCT05662189","Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus","Assessment of Pancreatic Beta Cell Mass and Function with the Aid of Positron Emission Tomography Imaging in Human Diabetes Mellitus","Inclusion Criteria:\n\n* Age ≥18 years; ≤ 75 years\n* Both sexes\n* Good health\n* Absence of exclusion criteria\n* Able to understand methods, goals, and implications of the research and of delivering a free, written informed consent\n\nExclusion Criteria:\n\n* Hemoglobin \\\u003C 12 g\u002Fdl\n* HbA1c \\> 10%\n* Pregnancy or breast-feeding\n* If not in menopause, women not using effective birth control methods or not willing to undergo a pregnancy test\n* History of severe psychiatric disorder or alcohol abuse\n* Recent head traumas (\\\u003C6 months)\n* Active neurologic diseases\n* Claustrophobia\n* Active malignant neoplasms\n* Severe kidney and\u002For liver disease\n* Recent (\\\u003C6 months) major adverse cardiovascular events\n* Heart failure (class NYHA 3-4)\n* Drugs known to affect beta cell function and\u002For insulin sensitivity\n* Current or past treatment with GLP1R-agonists\n* Intolerance to exenatide\n* Endocrine diseases, other than diabetes mellitus, known to affect beta cell function and\u002For insulin sensitivity, except well controlled hypothyroidism or adrenal insufficiency\n* COPD on day time oxygen therapy\n* Any current acute disease","ALL","18 Years","75 Years",{"count":94,"type":95},70,"ESTIMATED","INTERVENTIONAL",[98],"NA","The goals of this project are to build an experimental tool to dissect out in vivo pancreatic beta cell mass (BCM) and beta cell function (BCF) and to assess for the first time these two determinants of beta cell functional mass (BCFxM) in obesity and in various stages of type 1 and type 2 diabetes mellitus.",[101,102,103,104],"Type1diabetes","Type2diabetes","Pre Diabetes","Hyperinsulinism",[106,107,108,109],"diabetes","beta-cell","exendin","PET-CT","2025-03-14",{"date":112,"type":113},"2025-03-18","ACTUAL",{"date":115,"type":113},"2022-03-15",{"date":117,"type":95},"2025-12",{"name":5,"class":6},1]